Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Disarib |
Synonyms | |
Therapy Description |
Disarib is a small molecule inhibitor of BCL2, which targets the BH1 domain of BCL2, thereby interfering with the interaction between BCL2 and BAK, and subsequently, leading to apoptosis (PMID: 28223017). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Disarib | BCL2 inhibitor 27 | Disarib is a small molecule inhibitor of BCL2, which targets the BH1 domain of BCL2, thereby interfering with the interaction between BCL2 and BAK, and subsequently, leading to apoptosis (PMID: 28223017). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|